« Back to Record
Citation APA

Loibl, S., Loirat, D., Tolaney, S. S., Punie, K., Oliveira, M., Rugo, H. H., Bardia, A., Hurvitz, S., Brufsky, A., Kalinsky, K., Cortes, J., O'Shaughnessy, J., Diéras, V., Carey, L. L., Gianni, L., Gharaibeh, M., Preger, L., Phan, S., Chang, L., Shi, L., & Piccart-Gebhart, M. (2023). Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer. European journal of cancer, 178, 23-33. doi:10.1016/j.ejca.2022.10.003


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/371247

Loibl, S., Loirat, D., Tolaney, S. S., Punie, K., Oliveira, M., Rugo, H. H., Bardia, A., Hurvitz, S., Brufsky, A., Kalinsky, K., Cortes, J., O'Shaughnessy, J., Diéras, V., Carey, L. L., Gianni, L., Gharaibeh, M., Preger, L., Phan, S., Chang, L., Shi, L., & Piccart-Gebhart, M. (2023). Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer. European journal of cancer, 178, 23-33. doi:10.1016/j.ejca.2022.10.003